title: [BRAF: the pathologist's favorite oncogene].
authors: Service de pathologie, pôle de biologie clinique, pathologie, physiologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France. Electronic address: jean-christophe.sabourin@chu-rouen.fr.
authors: Jean-Christophe
authors: JC
authors: Sabourin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000494:pharmacology*; D007938:Leukemia / Q000139:chemically induced*; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008545:Melanoma / Q000556:secondary*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects* / Q000494:pharmacology*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf